Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07803692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years

Name: High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years — clinical trial record (NCT07803692)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HIFU for MRGE

StatusNot Yet Recruiting

PhaseNot applicable

SponsorOregon Health and Science University

Started2027-02

View on ClinicalTrials.gov ↗

The purpose of this study is to find out if magnetic resonance (MRI)-guided high-intensity focused ultrasound (HIFU) is safe and effective for treating medically refractory generalized epilepsy. HIFU is a procedure that delivers ultrasonic waves to brain regions with great precision to remove tissue that may cause problems. HIFU is approved by the Federal Drug Administration (FDA) for treating patients with essential tremor. This study aims to find out if HIFU can safely reduce seizure burden in patients with medically refractory generalized epilepsy (MRGE) using metrics commonly used in other treatments for epilepsy, and by the change in frequency of convulsive (generalized tonic-clonic) seizures before and after the intervention.

Trial Details

NCT Number	NCT07803692
Lead Sponsor	Oregon Health and Science University Collaborators: InSightec
Conditions	Idiopathic Generalized Epilepsy
Enrollment	10 participants
Start Date	2027-02
Primary Completion	2030-12 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-04